Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.

NCT04254549 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04254549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04254549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
June 14, 2019
Completion date
April 11, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, diabetic gastroparesis